Todd Matthew Morgan, MD

Todd M. Morgan, M.D. is a urological surgeon specializing in the treatment of genitourinary malignancies. Dr. Morgan is originally from Seattle, WA, and completed his undergraduate and medical training at Harvard University. He returned to the Northwest in 2003 for his urology residency at the University of Washington, before moving to Nashville for his fellowship training in urological oncology at Vanderbilt University. Dr. Morgan is a translational surgeon-scientist, and his research spans the spectrum from preclinical laboratory-based research to prospective clinical trials. The primary focus of his laboratory is on identifying key pathways that predict response and resistance to treatment in genitourinary malignancies. This includes work in prostate cancer to develop liquid biopsy approaches that can guide precision-based therapeutic strategies in real time, as well as ongoing research in renal cell carcinoma to identify genomic signatures for risk stratification.

Dr. Morgan is currently an Associate Professor of Urology and has been at the University of Michigan since 2012. In addition to his research pursuits, he is a busy clinician and surgeon offering advanced robotic, laparoscopic, and open surgical approaches for patients with genitourinary malignancies. He has substantial expertise in the use and interpretation of molecular biomarkers, which can help guide individualized treatment choice for some patients.

Beyond work, he loves his time enjoying the great town of Ann Arbor and beautiful state of Michigan with his wife, Wendy, and their two young boys. Whether camping in Petoskey, sitting on a beach in Grand Haven, or biking around the neighborhood in Ann Arbor, the Morgan family has quickly learned that life in the Midwest is hard to beat.

Prostate Cancer, including robotic prostatectomy and active surveillance; Bladder Cancer, including bladder preservation approaches as well as open and robotic radical cystectomy; Kidney Cancer, including open and robotic approaches, and nephron-sparing (i.e. partial nephrectomy) when appropriate; and Penile Cancer, including robotic inguinal lymphadenectomy.

University of Michigan Health participates with most health insurance plans.

Dr. Morgan runs a translational research laboratory focused on identifying biomarkers associated with treatment response, primarily through molecular profiling of tumor cells circulating in the blood and bone marrow of men with prostate cancer. The goal of this work is to be able to use a “liquid biopsy” to inform decisions in the same way that tissue-based biopsies currently do. These efforts also seek to shed light on how tumors learn to evade certain treatments and how these resistance mechanisms can be targeted. Dr. Morgan also directs a number of clinical trials, primarily focused on understanding how cancer biomarkers can be utilized in order to provide more individualized management approaches. His research has received funding from the National Cancer Institute (NCI), the Department of Defense, the Prostate Cancer Foundation, the Taubman Institute, and the National Comprehensive Cancer Network, among others.